Arrowhead Pharmaceuticals(US:ARWR)2026-02-05 22:32Financial Data and Key Metrics Changes - For Q1 2026, the company reported a net income of $30.8 million, translating to an income of $0.22 per share, a significant improvement from a net loss of $173.1 million or a loss of $1.39 per share in Q1 2025 [31] - Revenue for the quarter totaled $264 million, primarily driven by licensing collaborations with Sarepta and Novartis, with approximately $229 million from the Sarepta collaboration [31][32] - Total operating expenses increased to approximately $223 million from $164 million in the prior year, driven by higher R&D and SG&A expenses [33] Business Line Data and Key Metrics Changes - The company launched its first commercial product, Redemplo, approved for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS) [5][8] - Over 100 prescriptions for Redemplo have been received, with a balanced uptake across the U.S. [20] - The cardiometabolic pipeline includes ongoing studies for Zodasiran and new candidates ARO-INHBE and ARO-ALK7, with promising early results in weight loss and fat reduction [9][29] Market Data and Key Metrics Changes - The FDA approved Redemplo, marking a significant milestone for the company, with additional approvals from Health Canada and the Chinese National Medical Products Administration expected [8] - The company anticipates launching Redemplo in select EU countries and the U.K. later in 2026 [8] - The potential market for mixed hyperlipidemia, targeted by ARO-DimerPA, includes approximately 20 million people in the U.S. [11] Company Strategy and Development Direction - The company is focused on sustainable innovation and rational drug pricing, emphasizing the value offered to patients and healthcare systems [7] - Arrowhead aims to become cash flow positive and self-sustaining through multiple independent and partner launches, having completed transactions with gross proceeds of $1.33 billion [15][16] - The company is expanding its CNS portfolio with new delivery systems designed to penetrate the blood-brain barrier, targeting conditions like Alzheimer's disease [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position to build on recent achievements and highlighted the potential for significant growth in 2026 and beyond [5][37] - The company expects key events in 2026, including commercial sales progress for Redemplo and readouts from phase III studies for plozasiran [37] - Management remains optimistic about the early feedback from payers and healthcare providers regarding Redemplo [21][57] Other Important Information - The company has strengthened its balance sheet significantly, with cash and investments totaling $917 million as of December 31, 2025 [34][35] - The company is not disclosing specific sales numbers for Redemplo until they become a meaningful driver of financials [32] Q&A Session Summary Question: Can you provide a breakdown of patient categories for Redemplo? - The majority of patients are from the APOC3 naive segment, with the remaining balance split roughly 50/50 between switch patients and those transitioning from the expanded access program [41][42] Question: What are the timelines for discussions with the FDA regarding obesity treatments? - Discussions with the FDA are expected around mid-year, and an IND filing is anticipated shortly thereafter [44] Question: What level of reduction in LDL-C and triglycerides are you looking for with ARO-DimerPA? - A reduction of around 40%-50% in both LDL and triglycerides would be encouraging for advancing the asset [46][47] Question: How are you thinking about potential pricing for ARO-INHBE and ARO-ALK7? - It is too early to speculate on pricing as the company is still assessing the biology and potential efficacy of these candidates [50][51] Question: Can you discuss the pancreatitis event rates in ongoing trials? - The company is not providing additional details on event rates but acknowledges that events are being observed [53][54] Question: Has the pricing for Redemplo been discussed in relation to the SHTG market? - The focus is on ensuring coverage and access for high-risk patients, with discussions reflecting the clinical and economic value of Redemplo [56][59]